BioSpace News Archive

Ziopharm Oncology , Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”). Based on the consents received by the Company, Jaime Vieser and Holger Weis have been formally elected to the Ziopharm Board of Directors (the “Board”), while

Tecartus is First CAR T Therapy in Relapsed or Refractory MCL and Kite Becomes the First Company with Multiple Approved Cell Therapies in Europe

Arecor Limited, the biopharmaceutical company advancing ‘s therapies to enable healthier lives, today announces that Diabetes Care has published data for the Phase I clinical trial of AT247, its ultra-rapid acting insulin product candidate.

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced the closing of a $30 million Series C financing.

Global leader in specialty medical education teams up with Canada’s biggest bank to deliver exclusive support to the healthcare community

Further validation for Aroa’s Myriad™ from two clinical studies and peer-reviewed publications in Journal of Wound Care.

Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved Zolgensma® (onasemnogene abeparvovec) an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients with 5q spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene and 3 or fewer copies of SMN2 gene

Tetra will accelerate its Inhaled synthetic THC drug approvals under a 505(b)(2) marketing application pathway FDA confirms clinical development program to support marketing application of Tetras inhaled innovative THC drug

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC) and Paul Cox as Vice President of Investor Relations and Communications. “I am excited to welcome both William and Paul to Kymera. These key strategic

XWPharma Ltd. today announced that Michael M. Morrissey, Ph.D. has been appointed to the company’s Board of Directors